Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Solid Breakfast Meal Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effect of Food Form on Satiety and Gastric Emptying

NCT01102907
View directory record Official record
Conditions
Appetite
Interventions
Liquid Breakfast, Solid Breakfast Meal
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 8, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

NCT03516487
View directory record Official record
Conditions
Phenylketonuria, Healthy
Interventions
SYNB1618, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 8, 2026, 4:23 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

The Effects of a High Protein Breakfast on Appetite and Sleep in Young Adults

NCT03031132
View directory record Official record
Conditions
Appetite and General Nutritional Disorders
Interventions
HP-Beverage Breakfast, HP-Solid Breakfast, Breakfast Skipping
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
20 Years to 32 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 8, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

NCT01470209
View directory record Official record
Conditions
Solid Tumors, Lung Cancer
Interventions
BKM120, Everolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 8, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.

NCT01658436
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumors (pNET)
Interventions
BEZ235 (Stage 1)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • Boston, Massachusetts • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 8, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver

NCT00742911
View directory record Official record
Conditions
Cancer
Interventions
Disulfiram, Copper Gluconate
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 8, 2026, 4:23 PM EDT
Terminated Phase 1 Interventional

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

NCT05300048
View directory record Official record
Conditions
Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
Interventions
Serabelisib, Insulin Suppressing Diet, Nab paclitaxel
Drug · Other
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Anaheim, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 8, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 in Healthy Subjects

NCT01450098
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2484595 Reference Formulation (RF), LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 8, 2026, 4:23 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 8, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

NCT00046735
View directory record Official record
Conditions
Neoplasms
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 8, 2026, 4:23 PM EDT